Tirzepatide (Mounjaro); dapagliflozin, empagliflozin, metformin
Проводит Nazarbayev University
Страница компанииImproving the Diagnosis and Treatment of Cardiovascular Diseases in Kazakhstan by Introducing Correction of Metabolism With Glucagon-like Peptide 1 (GLP-1) Drugs
Источник: ClinicalTrials.gov (U.S. National Library of Medicine); Расчёт Клиномира. Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–75 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 120 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (11.2026) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 8 · невключение: 13
Критерии включения
- Chronic heart failure with preserved ejection fraction (left ventricular ejection fraction not ≤ 45%)
- Type 2 diabetes mellitus (T2DM) with HbA1c level between ≥7.0% and ≤10.5%
- Ongoing treatment for T2DM (e.g., metformin and/or sulfonylureas, or basal insulin therapy)
- Stable body weight (±5%) for at least 3 months prior to screening
- Body mass index (BMI) ≥ 25 kg/m²
- Possible inclusion of patients with chronic pancreatitis in remission
- Aged 18 years or older, and not older than 75 years
- Both male and female participants
Критерии невключения
- Type 1 diabetes mellitus
- Exacerbation of chronic pancreatitis
- Acute pancreatitis
- Proliferative diabetic retinopathy, diabetic maculopathy, or non-proliferative diabetic retinopathy
- History of bariatric (weight-loss) surgery or conditions associated with delayed gastric emptying
- Acute or chronic hepatitis
- Chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73 m²
- Myocardial infarction or stroke within the past 2 months
- Medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) in the participant or a first-degree relative
- Use of any other antidiabetic medications (except metformin and/or sulfonylureas and basal insulin) within the past 3 months
- Use of weight loss medications, including over-the-counter drugs, within the past 3 months
- History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorders within the past 2 years
- Healthy individuals (no cardiovascular or metabolic disease)
Источник: ClinicalTrials.gov, NCT07303556 · запись обновлена в реестре 28 января 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 5
- Change in NT-proBNP levels from baseline to Week 24 — Baseline to Week 24
Цель исследования
This clinical study aims to improve the diagnosis and treatment of cardiovascular diseases in Kazakhstan by Implementing Metabolic Correction with Glucagon-Like Peptide-1 (GLP-1). These medicines are called incretin-based therapies and include GLP-1 receptor agonists and a newer dual therapy that targets both GIP and GLP-1 receptors. Such medications have already shown benefits in lowering blood sugar, reducing body weight, improving blood pressure, and lowering the risk of serious heart complications.
Cardiovascular diseases and diabetes are among the most common health problems in Kazakhstan. Many patients remain undiagnosed or receive treatment only after their condition becomes severe. This study seeks to address these challenges by testing how well dual incretin therapy works in improving heart health, blood sugar control, and overall metabolic status in adults who have both chronic heart failure and type 2 diabetes.
Participants in the study will receive a detailed health evaluation at the beginning, including heart tests, blood work, and genomic profiling. Genomic testing will help researchers understand whether certain genetic features affect how patients respond to this therapy. After the initial assessment, participants will start treatment with a GIP/GLP-1 receptor agonist and will be monitored every few months for a total of 40 weeks. During these visits, their heart function, blood sugar levels, weight, and other health indicators will be checked to ensure both safety and effectiveness.
The main hypothesis of the study is that dual incretin therapy will improve heart function, reduce cardiometabolic risks, and show measurable benefits in patients with both chronic heart failure and type 2 diabetes. The study also assumes that a person's genetic profile may influence how well they respond to treatment.
By the end of the project, researchers hope to better understand how these medications work in the Kazakhstani population and to use these findings to support more personalized, effective, and modern approaches to treating cardiovascular diseases.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07303556 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, сроки, число участников, спонсор, центры
-
Расчёт Клиномира По датам из реестраСтатус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.